AIM IP specialist Tekcapital to sell or float all four portfolio companies 'within 2 years'. Watch the full video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAmryt Pharma Share News (AMYT)

Share Price Information for Amryt Pharma (AMYT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 167.50
Bid: 165.00
Ask: 170.00
Change: -5.00 (-2.90%)
Spread: 5.00 (3.03%)
Open: 172.50
High: 172.50
Low: 167.00
Yest. Close: 172.50
AMYT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

UK WINNERS & LOSERS SUMMARY: Amryt Surges Nearly 50% On Trial Results

Wed, 9th Sep 2020 10:50

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Wednesday.



FTSE 100 - LOSERS



AstraZeneca, down 0.9%. Clinical trials of one of the most advanced experimental Covid-19 vaccines, which is being developed by pharmaceutical company AstraZeneca and Oxford University, were "paused" Tuesday after a volunteer developed an unexplained illness. With billions of people around the world still suffering from the fallout of the pandemic and the global death toll nearing 900,000, a worldwide race for a vaccine is under way, with nine companies already in late-stage Phase 3 trials. A spokesperson for the AstraZeneca vaccine said in a statement Tuesday that "we voluntarily paused vaccination to allow review of safety data by an independent committee. "This is a routine action which has to happen whenever there is a potentially unexplained illness in one of the trials, while it is investigated, ensuring we maintain the integrity of the trials." The company said that in large trials, illnesses will sometimes happen by chance but must be reviewed independently. AstraZeneca didn't offer further details, but medical news site Stat News, which first reported the volunteer's illness, quoted a source saying it had involved a "serious adverse reaction" to the vaccine.



FTSE 250 - WINNERS



Computacenter, up 1.2%. The IT services firm reported profit growth for the first half, amid an increased demand due to Covid-19 pandemic, and said that it has agreed to buy Pivot Technology Solutions in Canada. Revenue for the first half of 2020 rose 1.5% to GBP2.46 billion from GBP2.43 billion year-on-year, while pretax profit grew by 43% to GBP72.4 million from GBP50.8 million. First half adjusted pretax profit totalled GBP74.6 million, up 39% year-on-year. The IT services firm said significant reductions in spend from industrial customers was offset by new business within the government and financial services sector. Separately, Computacenter said it has agreed to buy Toronto Stock Exchange-listed Pivot Technology Solutions. Computacenter will pay CAD2.60 cash for each Pivot share, the deal worth CAD105.8 million - nearly USD80 million or GBP62 million - based on the firm's 40.7 million shares.



FTSE 250 - LOSERS



JD Wetherspoon, down 6.5%. Leisure stocks were hit after the UK government tightened virus restrictions in England. The legal limit on social gatherings will be reduced from 30 people to six. It will apply to gatherings indoors and outdoors – including private homes, as well as parks, pubs and restaurants. Some 2,420 lab-confirmed cases of coronavirus were recorded in Britain as of 9am on Tuesday, following the 2,988 reported in the UK on Sunday, which was the largest daily figure since May. Marston's was down 8.9% and cinema chain operator Cineworld down 4.7%.



OTHER MAIN MARKET AND AIM - WINNERS



Amryt Pharma, up 46%. The biopharmaceutical company reported positive top line results from its pivotal phase 3 EASE trial of Filsuvez for the treatment of dystrophic and junctional epidermolysis bullosa. EASE is the largest phase 3 trial ever conducted in epidermolysis bullosa, which is a rare, chronic and distressing genetic skin disorder that causes the skin layers and internal body linings to separate. There are currently no approved treatments. The EASE trial was conducted in patients across 58 sites in 28 countries. It comprises a three month double-blind randomised controlled phase followed by a 24 month open-label, single-arm phase. The primary endpoint of the trial was to compare the efficacy of Filsuvez versus control gel according to the proportion of patients with complete closure of the target wound within 45 days of treatment. The primary endpoint was achieved, Amryt said.



OTHER MAIN MARKET AND AIM - LOSERS



Tullow Oil, down 11%. The South America and Africa-focused oil and gas company swung to a loss in the first half of 2020 after writing off more than USD900 million of exploration costs in Kenya and Uganda. Tullow turned to a USD1.31 billion loss for the six months ended June 30 from a USD387.6 million profit the year before. The company wrote off a total of USD941.4 million of exploration costs, compared to just a USD81.2 million write-off a year before. This USD941.4 million figure included a USD429.2 million write-off for Kenya Blocks 10BB and 13T due to a reduced long-term oil price assumption. Tullow also wrote off another USD417.5 million in Uganda in relation to a sale and purchase agreement with Total Uganda, part of Total SE. Under the agreement, Tullow agreed to transfer its interest in blocks Blocks 1, 1A, 2 and 3A in Uganda as well as the proposed East African crude oil pipeline system to Total. Additionally, revenue fell 16% to USD731.0 million in the recent half from USD872.3 million a year before, while cost of sales climbed 51% to USD567.0 million from USD375.1 million, resulting in a sharp gross profit drop of 69% to USD164.0 million from USD526.5 million.



Ryanair, down 2.4%. The Irish low-cost airline has reduced its annual passenger target to 50 million, Chief Executive Michael O'Leary told Reuters in an interview. Ryanair in July had guided to 60 million passengers in its current financial year, ending in March. In the 2020 financial year, Ryanair carried 149 million passengers. O'Leary said Ryanair is now guiding for 50 million passengers for the full year to the end of March, though added that "at the moment the way governments are handling it the risk is to the downside". The CEO told Reuters that fares will also be "aggressively down", and he thinks winter of 2020 "will essentially be a write-off". Other airline stocks were lower, with British Airways parent International Consolidated Airlines down 3.3% and easyJet down 4.7%.



By Lucy Heming; lucyheming@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News

TRADING UPDATES: SIG in good start to 2021; Accsys taps EUR37 million

TRADING UPDATES: SIG in good start to 2021; Accsys taps EUR37 million

5 May 21 19:20

EXECUTIVE CHANGES: Rosslyn promotes new CEO; Celtic CEO ready to start

EXECUTIVE CHANGES: Rosslyn promotes new CEO; Celtic CEO ready to start

6 Apr 21 14:54

Amryt completes rolling FDA submission for Oleogel-S10

(Sharecast News) - Commercial-stage biopharmaceutical company Amryt Pharma has completed the rolling submission of a new drug application (NDA) to the US Food and Drug Administration (FDA) for 'Oleogel-S10', it announced on Wednesday, for the potential treatment of cutaneous manifestations of junctional and dystrophic epidermolysis bullosa (EB).

31 Mar 21 11:50

Amryt releases data from Italy lomitapide study

(Sharecast News) - Commercial-stage biopharmaceutical company Amryt Pharma released efficacy and safety data from the 'Lochnes' investigator-sponsored study of lomitapide in familial chylomicronemia syndrome (FCS) on Tuesday, which was conducted by expert lipidologists in Italy.

30 Mar 21 12:11

European approval for Amryt's Oleogel-S10 moves closer

(Sharecast News) - Commercial-stage biopharmaceutical company Amryt Pharma announced the validation of its marketing authorisation application for 'Oleogel-S10' by the European Medicines Agency on Monday, for the potential treatment of cutaneous manifestations of junctional and dystrophic epidermolysis bullosa.

29 Mar 21 09:15

IN BRIEF: Amryt gets positive feedback on Myalept from US regulator

IN BRIEF: Amryt gets positive feedback on Myalept from US regulator

23 Mar 21 19:03

Amryt upbeat on positive FDA feedback

(Sharecast News) - Commercial-stage biopharmaceuticals company Amryt Pharma has received further feedback from the United States Food and Drug Administration (FDA) on Myalept, it said on Tuesday, and its proposed development plan and study design to support an indication for patients with partial lipodystrophy (PL).

23 Mar 21 09:34

IN BRIEF: Amryt's Myalepta secures reimbursement approval in France

IN BRIEF: Amryt's Myalepta secures reimbursement approval in France

22 Mar 21 19:07

Amryt's Myalepta gets reimbursement approval in France

(Sharecast News) - Commercial-stage biopharmaceuticals company Amryt Pharma announced on Monday that the French Ministry of Social Affairs and Health has approved 'Myalepta', or metreleptin, for reimbursement in the country as an adjunct to diet as replacement therapy.

22 Mar 21 09:04

Director dealings: Amryt Pharma chairman makes share purchase

(Sharecast News) - Amryt Pharma revealed on Monday that chairman Ram Stafford had acquired 300,100 ordinary shares in the AIM-listed commercial-stage biopharmaceutical company.

15 Mar 21 16:38

IN BRIEF: Amryt, Medison sign distribution deal for Myalepta in Canada

IN BRIEF: Amryt, Medison sign distribution deal for Myalepta in Canada

9 Mar 21 06:55

Amryt Pharma signs another distribution deal with Medison

(Sharecast News) - Commercial-stage biopharmaceutical company Amryt Pharma announced the signing of a distribution agreement with Medison Pharma to distribute 'Myalepta' in Canada on Monday.

8 Mar 21 12:19

TRADING UPDATES: Origin Enterprises loss slims; Amryt issues guidance

TRADING UPDATES: Origin Enterprises loss slims; Amryt issues guidance

4 Mar 21 12:46

Amryt signs multi-regional distribution deals with Medison

(Sharecast News) - Commercial-stage biopharmaceuticals company Amryt Pharma announced the signing of multi-regional distribution agreements with Medison Pharma on Thursday.

4 Feb 21 14:18

Amryt Pharma Signs Drug Distribution Agreements With Medison Pharma

Amryt Pharma Signs Drug Distribution Agreements With Medison Pharma

4 Feb 21 12:14

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.